Document ID: 15287

Text:
76,359,923 are issued and outstanding, (ii) 12,768,492 shares of Evofem Series A Preferred Stock, par value $0.001 per share of which 12,618,279 have been issued and are outstanding, (iii) 31,034,696 shares of Evofem Series B Preferred Stock, par value $0.001 per share, of which 13,801,318 shares are issued and outstanding, (iv) 5,037,784 shares of Company Series C Preferred Stock of which 5,037,784 shares are issued and outstanding, (v)8,660,572 shares of Evofem C-1 Preferred Stock, par value $0.001 per share, of which 8,558,686 shares are issued and outstanding, (vi)80 shares of Evofem Series D Preferred Stock, par value $0.001 per share, of which 75 are issued and outstanding. No shares of capital stock are held in Evofems treasury. All outstanding shares of capital stock of Evofem are duly authorized, validly issued, fully paid and non-assessable and were issued in compliance with all applicable federal and state securities laws. Immediately prior to the Effective Time of the Merger (assuming the Effective Time occurs on December31, 2017 and after giving effect to the conversion of the Company Preferred Stock (other than the Company Series D Preferred Stock) and the exercise of the Warrant as contemplated by the Merger Agreement), Evofems capitalization shall be as set forth on Exhibit E hereto.

Named Entities:
0
4
Shares
13
17
Shares
28
31
Principal
36
40
Shares
51
55
Shares
75
79
Shares
89
93
Shares
117
121
Shares
140
144
Shares
275
276
Title

Tokenized Text:
76
,
359
,
923
are
issued
and
outstanding
,
(
ii
)
12
,
768
,
492
shares
of
Evofem
Series
A
Preferred
Stock
,
par
value
$
0
.
001
per
share
of
which
12
,
618
,
279
have
been
issued
and
are
outstanding
,
(
iii
)
31
,
034
,
696
shares
of
Evofem
Series
B
Preferred
Stock
,
par
value
$
0
.
001
per
share
,
of
which
13
,
801
,
318
shares
are
issued
and
outstanding
,
(
iv
)
5
,
037
,
784
shares
of
Company
Series
C
Preferred
Stock
of
which
5
,
037
,
784
shares
are
issued
and
outstanding
,
(
v
)
8
,
660
,
572
shares
of
Evofem
C-1
Preferred
Stock
,
par
value
$
0
.
001
per
share
,
of
which
8
,
558
,
686
shares
are
issued
and
outstanding
,
(
vi
)
80
shares
of
Evofem
Series
D
Preferred
Stock
,
par
value
$
0
.
001
per
share
,
of
which
75
are
issued
and
outstanding
.
No
shares
of
capital
stock
are
held
in
Evofems
treasury
.
All
outstanding
shares
of
capital
stock
of
Evofem
are
duly
authorized
,
validly
issued
,
fully
paid
and
non-assessable
and
were
issued
in
compliance
with
all
applicable
federal
and
state
securities
laws
.
Immediately
prior
to
the
Effective
Time
of
the
Merger
(
assuming
the
Effective
Time
occurs
on
December31
,
2017
and
after
giving
effect
to
the
conversion
of
the
Company
Preferred
Stock
(
other
than
the
Company
Series
D
Preferred
Stock
)
and
the
exercise
of
the
Warrant
as
contemplated
by
the
Merger
Agreement
)
,
Evofems
capitalization
shall
be
as
set
forth
on
Exhibit
E
hereto
.